Results 51 to 60 of about 231,116 (154)

Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies

Genitourinary (GU) malignancies are common and associated with significant morbidity and mortality. In patients with localized GU cancers, surgical resection or definitive radiation remain the mainstays of treatment.
Amir Mortazavi, Eric A. Singer, Shawn Dason, Dharmesh Gopalakrishnan, Karan Jatwani, Yuanquan Yang, Adam Khorasanchi, Gurkamal Chatta, Katharine A. Collier, Debasish Sundi, Lingbin Meng   +10 more
core   +1 more source

History and current situation of neoadjuvant treatment for locally advanced esophageal cancer

Thoracic Cancer, 2021
Esophageal cancer is one of the most commonly diagnosed malignant tumors, especially in north China. Surgery is one of the major treatments. However, for locally advanced cases, surgery alone does not achieve an ideal prognosis.
Junyi Li, Shaohua Ma
doaj   +1 more source

The promise of neoadjuvant immunotherapy and surgery for cancer treatment

, 2019
Cancer immunotherapies utilizing immune checkpoint inhibitors (ICI) have demonstrated durable efficacy in a proportion of patients with advanced/metastatic cancers.
Smyth, Mark J., O'Donnell, Jake S., Hoefsmit, Esmee P., Teng, Michele W.L., Blank, Christian U.   +4 more
core   +1 more source

The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer

Despite advances in treatment strategies and surgical approaches in recent years, improving survival outcomes in esophagogastric cancer (EGC) patients treated with curative intent remains a significant area of unmet need. The recent emergence of adjuvant
Vincent K. Lam, Alisha F. Khan, Colum Dennehy, Ali H. Zaidi   +3 more
core   +1 more source

Neoadjuvant immunotherapy in breast cancer: A paradigm shift?

, 2020
Despite advances in clinical management, a proportion of patients with early-stage triple-negative breast cancer (TNBC) recur after local treatment.
Ignatiadis, Michail, Fountzila, Elena
core   +1 more source

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

, 2023
Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard ...
Eggermont A. M. M., Schadendorf D., Lebbe C., van de Wiel B. A., Blank C., Nathan P., Moreno D., Robert C., Amaria R. N., Michielin O., Tawbi H. A., Scolyer R. A., Hoeller C., Garbe C., Dummer R., Ascierto P. A., Hauschild A., Amaral T., Kaufmann R., Dreno B., Lorigan P. C., Patel S. P., Mandala' M., Long G. V., Burton E. M., Menzies A. M.   +25 more
core   +1 more source

Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study

Cancer Immunology, Immunotherapy
Purpose The value of adjuvant immunotherapy in patients with resectable stage III non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy remains unclear.
Song Guan, Hui Wang, Zhaoxin Chen, Fengrui Guo, Guozhen Yi, Xingyu Du, Jingjing Yan, Cuimeng Tian   +7 more
doaj   +1 more source

Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients

Медицинский совет, 2019
Nowadays neoadjuvant immunotherapy is one of the main research areas in oncology. This interest is supported by the success of check-point inhibitors in treatment of advanced and metastatic lung cancer.
K. K. Laktionov, V. V. Breder, D. I. Yudin, K. A. Sarantseva, L. V. Laktionova, M. S. Ardzinba, E. V. Reutova, A. V. Egorova   +7 more
doaj   +1 more source

Adding Neoadjuvant Immunotherapy to Chemotherapy in Non-Metastatic Triple-Negative Breast Cancer: A Propensity-Matched Cohort Study from a Tertiary Cancer Center

Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Immunotherapy has recently emerged as a potential strategy.
Safi, Yasmin, Ramiz Kardan, Ramadan, Ola, Mustafa, Daliana, AlMasri, Rama, Ola Ramadan, Al-Masri, Mahmoud, Yasmin Safi, Mahmoud Al-Masri, Rama AlMasri, Daliana Mustafa, Kardan, Ramiz   +11 more
core   +1 more source

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature

, 2022
Non-small cell lung cancer accounts for approximately 80–85% of all lung cancers and at present represents the main cause of cancer death among both men and women.
Giorgio Alberto Croci, Rijavec, Erika, Tosi, Davide, Croci, Giorgio Alberto, Erika Rijavec, Mattioni, Giovanni, Franzi, Sara, Giovanni Mattioni, Davide Tosi, Sara Franzi   +9 more
core   +1 more source